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Non-metastatic prostate cancer: rationale for conservative treatment and impact
on disease-related morbidity and mortality in the elderly
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aSection of Urology, Vestfold Hospital Trust, Tønsberg, Norway; bDepartment of Clinical Medicine, University of Bergen, Bergen, Norway;
cInstitute of Population-Based Cancer Research, Cancer Registry of Norway, Oslo, Norway; dDepartment of Urology, Haukeland University
Hospital, Bergen, Norway
ABSTRACT
Purpose: To determine the rationale for not offering local treatment to prostate cancer patients with
non-metastatic disease at diagnosis who later died of prostate cancer and to document local and sys-
temic complications caused by disease progression.
Material and Methods: In this population-based, retrospective study we reviewed the medical records of
all patients who died of prostate cancer in 2009–2014 in Vestfold County (Vestfold Mortality Study), who
were non-metastatic at diagnosis and who had received no local treatment to the prostate (n¼ 117).
Results: A review of patient records demonstrated that the chronological age of 75 years or older was
the main rationale for not offering local treatment to the prostate (37%, n¼ 43). No consideration was
given to the functional status and patient health. These elderly patients stood for almost one-fifth of
the total PC mortality in Vestfold County. In addition to dying from PC, 86% of patients developed
local complications attributable to PC progression. Observation of strict limits for local treatment with
regard to tumor characteristics contributed further to the underuse of local treatment.
Conclusions: Our study demonstrated systematic undertreatment of elderly patients with aggressive, non-
metastatic PC with regard to local treatment based on chronological age alone. The patients in this study
died of prostate cancer and the majority experienced significant morbidity caused by local tumor growth.
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Reducing prostate cancer mortality is the main objective of
prostate cancer treatment. Early detection followed by local
treatment of the prostate either by surgery or radiation is
important means for achieving this goal [1–4].
The Vestfold Mortality Study, which examined the validity
of death certificates in determining the cause of death of
prostate cancer (PC) patients, identified 255 men who died of
PC in Vestfold County, Norway, during the 6-year period
2009–2014 [5]. More than half of these patients (n¼ 139; 55%)
had non-metastatic PC (NMPC) at diagnosis and thus poten-
tially curable disease. Unexpectedly, only 16% of these had
been offered local treatment. The median age of patients who
had received no local treatment was 75 years suggesting that
age might have influenced treatment decisions.
Incidence rates of high-risk and locally advanced PC increase
with age [6], while guidelines with regard to local treatment of
elderly patients with PC are usually vague. The current EAU
guidelines suggest that patients with high-risk, localized PC
should have a life expectancy of 10 years or more to be eligible
for local treatment while no guidance on patient age is pro-
vided for patients with locally advanced PC [7].
The aim of this study was to identify the rationales for
offering no local treatment to the prostate in NMPC patients
in Vestfold County who later died of PC. Furthermore, we
documented systemic and local interventions and complica-
tions caused by disease progression.
Material and methods
Patient population
Vestfold Hospital Trust provides PC care for all patients in
Vestfold County (Population 240,000, the average annual
number of new PC cases 2013–2017: 263) including diagno-
sis, treatment and follow-up, allowing for access to almost
complete patient data. Among the 255 patients who died of
PC in 2009–2014 in Vestfold County (Vestfold Mortality Study
database) [5], we identified 139 patients with NMPC at diag-
nosis. A hundred and seventeen (84%) of these patients had
not been offered local treatment. Metastatic status was
determined by the imaging method available at the time of
diagnosis (bone scan, CT, MRI).
Methods
We deducted the rationales for choosing curative versus non-
curative treatment from the patient records at the time of
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diagnosis based on the stated or implied reasoning of the
treating doctor. Patients were assigned to two groups accord-
ing to the decision rationale: Patients who had not received
curative treatment due to age (NoTreat/age) and patients who
had not received local treatment due to other reasons
(NoTreat/other)
We assessed patient performance status retrospectively
using the Eastern Cooperative Oncology Group score (ECOG)
[8] differentiating patients with good performance status
(ECOG 0 and 1) from patients with reduced performance sta-
tus (ECOG  2). We recorded patient comorbidity using the
Charlson comorbidity index (CCI) and estimated 10-year sur-
vival using the age-adjusted Charlson-score (CS) [9].
We collected data on patient survival, tumor characteris-
tics at diagnosis, use of systemic therapy/radiation to bone/
prostate and local complications during the course of the
disease from patient records.
Statistics
All statistical analyses for the Vestfold patients were con-
ducted using SPSS statistics, version 23 (IBM Corp., Armonk,
NY). We described baseline data by the median, interquartile
range and percentages.
Results
Rationale for treatment decision
Of the 117 patients with non-metastatic PC at diagnosis who
had not received local treatment, 73 (62%) were initially
treated with hormones, while 44 patients (38%) were fol-
lowed with watchful waiting.
Analysis of the decision process identified chronological
age as the reason for abstaining from curative treatment in
37% of patients (NoTreat/age, n¼ 43). Patients in this sub-
group stood for 17% of all PC deaths in Vestfold County dur-
ing the study period and for more than 30% of PC deaths
with NMPC at diagnosis. Figure 1 shows the complete list of
rationales for choosing hormonal treatment or watchful wait-
ing for the study population.
The median age at diagnosis in the NoTreat/age and NoTreat/
other groups was 79 and 70years respectively, and the median
time from diagnosis to death was 7 and 8 years, respectively.
Ninety-one percent of patients in the NoTreat/age group
were in good functional shape at the time of diagnosis
(ECOG 1) and 86% of patients were in excellent or good
health (Charlson comorbidity index/CCI 1) (Figure 2).
Almost all NoTreat/age patients had either locally
advanced or localized high-risk PC at diagnosis. Table 1 sum-
marizes the clinical characteristics of both patient groups.
The median year of diagnosis for all patients was 2003
(IQR 2001–2007). Median year of diagnosis for patients in the
NoTreat/age group was 2005 while the median year of diag-
nosis for patients in the NoTreat/other group was 2002.
PC related morbidity
In addition to dying from PC, 86% of patients in the
NoTreat/age group developed local complications during the
course of their disease. More than half of the patients
needed bladder catheterization, 20% a nephrostomy and
10% a colostomy (see Figure 3).
Nineteen percent of patients received radiation to the
bone (n¼ 8), 7% were treated with docetaxel alone (n¼ 3)
and 14% were treated with various combinations of palliative
therapies. Only one patient (2%) received abiraterone alone
and no patient was treated with enzalutamide alone. Almost
60% of patients received no second-line treatment (n¼ 25).
Figure 1. Rationales for offering conservative treatment or watchful waiting in non-metastatic patients in the Vestfold Mortality Study (N¼ 117). Positive lymph
nodes were diagnosed by surgical lymph node staging. According to national treatment protocols, at the time positive lymph nodes were a contraindication for
radical treatment.
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Forty-seven percent of NoTreat/age patients (n¼ 20) received
blood transfusions at least once due to cancer-induced anemia.
Discussion
In this retrospective, population-based study, we found that
many patients with lethal PC but potentially curable disease at
diagnosis did not receive local treatment of the prostate based
on their chronological age alone (75years). In addition to
dying of PC, the majority of these patients experienced consid-
erable morbidity caused by the local progression of PC.
There is increasing awareness that elderly patients with
cancer are undertreated, particularly with regard to local,
curative therapy [10–12]. For PC globally, the large majority
of elderly patients with NMPC has been treated conserva-
tively with hormone therapy or followed with watchful wait-
ing, partly due to a lack of documented benefit of treatment
Figure 2. Charlson Comorbidity Index (CCI, left) and ECOG performance status (right) at diagnosis for patients with non-metastatic prostate cancer who received
no local treatment due to age (NoTreat/Age, N¼ 43).




No. of patients 74 43
Median age at diagnosis (IQR) 70 (63–75) 79 (76–83)
Median age at death (IQR) 79 (72–84) 87 (86–89)
Median time diagnosis to death, years (IQR) 8 (5–11) 7 (5–9)
ECOG at diagnosis, No (%)
0 54 (73) 8 (19)
1 10 (14) 31 (72)
2 10 (14) 4 (9)
Median estimated 10-year survival at diagnosis by Charlson score , % (IQR) 77 (53–90) 53 (53–77)
Tumor characteristics at diagnosis
Median PSA, mG/L (IQR) 18 (13–34) 26 (15–51)
ISUP grade group, No (%)
ISUP group 1 (Gleason 6) 13(17)
ISUP group 2 (Gleason 7A) 23 (31) 13 (30)
ISUP group 3 (Gleason 7B) 9 (12) 9 (21)
ISUP group 4 (Gleason 8) 16 (22) 9 (21)
ISUP group 5 (Gleason 9þ 10) 7 (9) 7 (16)
Unknown 6 (8) 1 (2)
T stage, No (%)
T1 19 (26) 10 (23)
T2 14 (19) 9 (21)
T3 38 (51) 19 (44)
T4 3 (4) 5 (12)
CRPC at death
No. of patients with CRPC (%) 74 (100) 43 (100)
Median time diagnosis to CRPC, years (IQR) 4 (2–8) 4 (2–6)
Metastasis at death, No (%)
Mþ 70 (95) 40 (93)
M 4 (5) 3 (7)
Patients not treated locally for other reasons than age (NoTreat/Other) and patients not treated locally due to patient age (NoTreat/Age).
PC: prostate cancer; NoTreat/other: no local/ curative treatment for other reasons than age; NoTreat/age: no local/ curative treatment due
to patients age; CRPC: castrate-resistant prostate cancer; IQR: interquartile range; ISUP: International Society of Urological Pathology.Metastatic status unknown.
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with curative intent [13]. In Norway NMPC in elderly patients
was regarded as a condition conferring little risk for patients
in terms of mortality and morbidity, regardless of PC grade
and stage [14]. In our study, we further documented that in
addition to age, stringent national thresholds (PSA, lymph
node status) for offering local treatment 10–15 years ago,
excluded patients that would be eligible for local treatment
according to current guidelines [7].
There is today compelling evidence that locally advanced
and high-risk PC is a deadly disease regardless of age. A US
study, based on SEER-Medicare data, demonstrated a 10-year
cancer specific-mortality of 27% for patients older than
75 years with high-risk, localized PC [15]. A Swedish nation-
wide register-based study found that even in patients older
than 85 years, untreated, locally advanced PC with Gleason
grade 8–10 was associated with a mortality rate of 42% [16].
The authors suggest that “locally advanced tumors carry an
entirely different prognosis and that considerably higher
stakes may be justified in the choice of treatment.” A further
study from Sweden showed clear underuse of radical therapy
in elderly patients [17]. In support of these findings, Sheng
and colleagues found a positive impact of local treatment on
cancer-specific mortality compared to conservative treatment
in elderly patients (aged  75 years, locally advanced PC).
However, the benefit was only seen in patients with cT3b/4
tumors, Gleason score 8–10, negative lymph nodes or PSA >
10 ng/ml [18].
A recent publication of data from the National Cancer
Database (NCDB) that captures approximately 70% of newly
diagnosed cancers in the United States, documented that
increasing age was significantly associated with a decreased
likelihood of curative treatment in patients with intermediate
and high-risk PC. Interestingly, despite the evidence of
undertreatment, the study showed that more than half of
patients older than 80 years had received some form of local
treatment, mostly radiotherapy [19]. This stands in contrast
with treatment policies in Norway: In 2004 less than 5% of
patients aged 75–79 years had received local treatment, with
gradually increasing treatment numbers during the course of
the following 12 years (50% local treatment in 2016).
However, even in 2016 only slightly more than 10% of
patients older than 80 years had received local therapy
(radiotherapy, 70Gy, 12months of diagnosis) [14]. Similar
findings are published from Sweden reflecting a Scandinavia-
wide policy of stringent age criteria for offering local treat-
ment a decade ago [6]. This is surprising, as life expectancy
for elderly men in Norway is high. For example, an 80-year-
old Norwegian man had in 2018 an average life expectancy
of 8.5 years (Source: Statistics Norway, www.ssb.no).
Controlling localized high-risk or locally advanced PC over
such prolonged periods of time without local treatment to
the prostate may prove challenging.
The data presented in this study support this latter notion
by highlighting another aspect of insufficient tumor control:
Failure to offer local treatment may lead to considerable
local complications during the further course of the disease.
More than 80% of the elderly patients in our study experi-
enced at least one complication that could be attributed to
local tumor growth and a considerable number of patients
had to live with long-term interventions such as catheteriza-
tion, nephrostomies and colostomies.
As the median time from diagnosis to (prostate cancer)
death in our population was only 7 years, the generally
accepted policy at the time of offering local treatment only to
patients with a life expectancy of more than 10years seems
inadequate. With hormone therapy, the median time to cas-
tration-resistance was 4 years. For many elderly patients, this
is insufficient to avoid PC mortality and morbidity.
In terms of cancer morbidity other than local complica-
tions, almost half of the patients received blood transfusions.
Figure 3. Local complications during the course of the disease in patients with no local/curative treatment due to age (NoTreat/Age, N¼ 43). The total incidence
of >100% is a result of the occurrence of two or more complications in a single patient.
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Only a minority received systemic second-or third-line therapy
after the onset of castration-resistance (CRPC). This may reflect
the functional status and health of patients who were unfit
for treatment with docetaxel, as abiraterone and enzalutamide
were not available at the time in Norway as first-line treat-
ment for patients with CRPC. According to recent publications
[20,21], it is reasonable to assume that considerably more eld-
erly patients will be eligible for abiraterone and/or enzaluta-
mide as first- and second-line treatment of CRPC. Thus, early
local therapy may reduce not only tumor progression but also
the occurrence of CRPC and consequently the need for a
costly second- and third-line systemic therapy.
There is however an important caveat: Introducing routine
local treatment of PC in elderly high-risk patients may create
yet another area of overtreatment and potentially beneficial
treatment effects must be weighed against side effects [22].
Our study offers no indication of the scope of potential over-
treatment. The role of routine local treatment in elderly
high-risk and locally advanced NMPC patients with good
functional status and health should thus be addressed by
randomized trials and age as a sole exclusion criterion in this
patient group ought to be abandoned.
With a retrospective design, there are obvious limitations
to our study. However, the strength lies in the high quality
of the data on comorbidity, functional status, local/systemic
complications and other clinical information. Furthermore,
the regional restriction and the small number of patients
could be a weakness.
In summary, among NMPC patients who died of PC in
Vestfold in 2009–2014 only a minority received local/curative
therapy. For these patients, the lack of adequate local ther-
apy had considerable consequences in terms of local tumor
growth/morbidity and systemic complications. The study
suggests that a more active approach in the use of local
therapy in elderly patients with high-risk or locally advanced
NMPC has the potential of reducing disease-related morbid-
ity and mortality.
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